Moody’s says Pfizer’s U.S. COVID-19 vaccine authorization is credit positive By Reuters

© Reuters. FILE PHOTO: A vial of the Pfizer/BioNTech COVID-19 vaccine is seen at the Royal Victoria Hospital in Belfast

(Reuters) – Rating agency Moody’s (NYSE:) Investors Service said on Sunday that Pfizer Inc (NYSE:)’s U.S. COVID-19 vaccine authorization is credit positive.

The approval is credit positive because of incremental profit and cash flow from sales of the vaccine,” Moody’s said https:// “The revenue and profit opportunities for Pfizer are significant because it has priced the vaccine at a profit.”

The Pfizer/BioNTech vaccine in a large clinical trial was 95% effective in preventing illness. U.S. regulators late on Friday authorized emergency use of the vaccine, following similar moves by the UK and Canada.

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *